Compare · BIIB vs IVVD
BIIB vs IVVD
Side-by-side comparison of Biogen Inc. (BIIB) and Invivyd Inc. (IVVD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIIB and IVVD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BIIB is the larger of the two at $29.53B, about 130.2x IVVD ($226.8M).
- Over the past year, BIIB is up 52.7% and IVVD is down 3.4% - BIIB leads by 56.1 points.
- BIIB has been more active in the news (18 items in the past 4 weeks vs 4 for IVVD).
- BIIB has more recent analyst coverage (25 ratings vs 7 for IVVD).
- Company
- Biogen Inc.
- Invivyd Inc.
- Price
- $200.00+0.04%
- $0.76-6.33%
- Market cap
- $29.53B
- $226.8M
- 1M return
- -2.21%
- -48.54%
- 1Y return
- +52.66%
- -3.45%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 18
- 4
- Recent ratings
- 25
- 7
Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest BIIB
- Director Hawkins William A was granted 1,505 shares, increasing direct ownership by 17% to 10,365 units (SEC Form 4)
- Director Sherwin Stephen A was granted 1,505 shares, increasing direct ownership by 11% to 15,193 units (SEC Form 4)
- Director Rowinsky Eric K was granted 1,505 shares, increasing direct ownership by 6% to 25,844 units (SEC Form 4)
- Director Mantas Jesus B was granted 1,505 shares, increasing direct ownership by 15% to 11,263 units (SEC Form 4)
- Director Langer Susan was granted 1,505 shares, increasing direct ownership by 29% to 6,634 units (SEC Form 4)
- Director Patolawala Monish D was granted 1,505 shares, increasing direct ownership by 41% to 5,215 units (SEC Form 4)
- Director Pangalos Menelas N converted options into 2,370 shares and was granted 1,505 shares (SEC Form 4)
- Director Minor Lloyd was granted 1,505 shares, increasing direct ownership by 64% to 3,875 units (SEC Form 4)
- Director Freire Maria C was granted 2,005 shares, increasing direct ownership by 29% to 8,820 units (SEC Form 4)
- Biogen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
Latest IVVD
- Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safety and Immunology of Antibody and mRNA Vaccine Co-Administration
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Invivyd Announces Completion of Enrollment in Upsized DECLARATION Clinical Trial, a Phase 3 Pivotal Study of VYD2311, an Investigational Antibody to Prevent COVID
- Invivyd to Participate in Upcoming Investor Events
- SEC Form 4 filed by Director Royan Ajay
- SEC Form 4 filed by Director Mcguire Terrance
- SEC Form 4 filed by Director Mclaughlin Kevin F
- SEC Form 4 filed by Director Elia Marc
- SEC Form 4 filed by Director Bolno Paul
- SEC Form 4 filed by Director Berry Tamsin